Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe, Oceania, and the United States of America (USA).
The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart
(IDegAsp)) with insulin detemir (IDet) plus insulin aspart in patients with type 1 diabetes
(main period) followed by the extension period comparing the long-term safety of NN5401 plus
insulin aspart with insulin detemir plus insulin aspart.
The main period is registered internally at Novo Nordisk as NN5401-3594 while the extension
period is registered as NN5401-3645.